Contineum Therapeutics (CTNM) EBITDA (2023 - 2026)

Contineum Therapeutics' EBITDA history runs 4 years deep, the most recent figure standing at -$17.4 million for Q2 2026.

• In Q2 2026, EBITDA rose 2.65% year-over-year to -$17.4 million; the TTM figure through Jun 2026 stood at -$66.4 million (down 0.52% YoY), while the FY2025 annual figure was -$68.1 million, down 33.73% from the prior year.
• EBITDA for Q2 2026 stood at -$17.4 million, down from -$16.9 million in the prior quarter.
• The five-year high for EBITDA was $38.9 million in Q2 2023, with the low at -$18.1 million in Q1 2025.
• The 4-year median for EBITDA is -$14.0 million (2024), against an average of -$9.8 million.
• The sharpest annual moves came in 2024 and 2026: EBITDA plunged 128.11% in 2024, then increased 6.66% in 2026.
• Contineum Therapeutics' EBITDA stood at -$9.7 million in 2023, then sank by 76.18% to -$17.0 million in 2024, then dropped by 0.4% to -$17.1 million in 2025, then declined by 1.83% to -$17.4 million in 2026.
• Business Quant data shows CTNM's EBITDA at -$17.4 million in Q2 2026, -$16.9 million in Q1 2026, and -$17.1 million in Q4 2025.